Tamoxifen

A prescription SERM approved for treatment and risk reduction of certain breast cancers. It is sometimes misused after anabolic-steroid exposure to counter suppression, but that use is unapproved and no standardized recovery regimen is established.

Tamoxifen is a selective estrogen receptor modulator (SERM): it blocks the estrogen receptor in some tissues while acting like estrogen in others. That tissue selectivity is the whole point. In the breast it is anti-estrogenic (its cancer use). At the hypothalamus and pituitary it blocks the estrogen feedback that normally suppresses LH and FSH, so those signals rise and the testes are told to produce more testosterone — the basis of its use in male hormone recovery and in gynecomastia. Crucially it lowers oestrogen SIGNALLING without lowering circulating estradiol the way an aromatase inhibitor does — but bone outcomes in steroid-using men are not established, and tamoxifen's skeletal effects vary by sex and hormonal state, so "no bone cost" is not a claim the evidence supports.

Decades of oncology data. No randomised evidence establishes tamoxifen as a treatment for steroid-induced hypogonadism or proves it restores fertility or endogenous testosterone; the recovery use rests on survey and retrospective reports, not controlled trials.

• Oncology evidence is vast and high quality — decades of large randomised trials in breast cancer prevention and treatment.
• Graded honestly: breast-cancer treatment and risk reduction STRONG; biochemical effects in men (raised LH, FSH and testosterone via relieved oestrogen feedback) LIMITED to MODERATE; and steroid-withdrawal recovery LIMITED, with no proven regimen and no guaranteed clinical benefit. The randomised gynecomastia trials concern idiopathic and antiandrogen-induced cases — for steroid-associated gynecomastia specifically the evidence is case-level, not trial-level.
• For the specific job of restarting the hormonal axis after suppressive steroid use, the human evidence is real but thinner and mostly short-term; it is a legitimate clinical tool used off-label, not a guaranteed reset.

An oral drug with a long half-life (its active metabolites persist for days to over a week), so it reaches steady state slowly and clears slowly. It is metabolised by the liver via CYP2D6 into endoxifen, its main active form — which is why anything that blocks CYP2D6 blunts it, and why the DIM interaction (which lowers endoxifen) matters.

Reported risks include thromboembolism and stroke (the serious ones, especially with other risk factors), cataracts and other ocular effects, mood and libido changes. New visual symptoms require prompt medical assessment. Recovery of a suppressed axis is not guaranteed regardless of what is taken.

• Anyone with a personal or family history of blood clots, or other thrombosis risk factors — this is the headline danger.
• Anyone on a CYP2D6-inhibiting antidepressant, where it may not work as intended.
• Anyone treating a non-estrogenic side effect with it (it will not touch prolactin-driven gynecomastia from nandrolone or trenbolone).
• Anyone who would be better served by a clinician-run recovery, which is most people attempting it alone.

• CYP2D6 inhibitors (some SSRIs, notably paroxetine and fluoxetine) reduce conversion to endoxifen. That pharmacokinetic effect is documented; current labelling says the impact on tamoxifen efficacy is NOT well established, so this is a prescriber conversation rather than a proven treatment failure.
• Coumarin anticoagulants such as warfarin — the labelled interaction is a SUBSTANTIAL INCREASE in anticoagulant effect and bleeding risk, which is separate from tamoxifen's own clot risk and runs the opposite direction.
• DIM altered tamoxifen metabolite concentrations including endoxifen in one randomised trial, as a secondary finding; what that means for any clinical outcome is unknown — a real interaction with the supplement, not a footnote.
• Anastrozole levels fall when the two are combined, one reason they are not simply stacked.
• Anticoagulants — the combined effect on clotting compounds tamoxifen's own thrombotic risk.

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

• LH, FSH and total testosterone — the axis it is meant to move; the point of a recovery attempt is to see these rise.
• Label-level harms this entry must not omit: uterine and endometrial malignancy and any abnormal vaginal bleeding, fetal harm requiring non-hormonal contraception, breastfeeding risk, hypercalcaemia in bone metastases, low blood counts and liver effects.
• Symptoms of the estrogenic actions it keeps: it does not crash estradiol, so estrogen-deficiency symptoms are not the concern; mood and vision changes occasionally reported are.
• Lipids and liver markers on longer use.
• A specific and serious one: signs of venous thromboembolism (leg swelling, chest pain, breathlessness) — tamoxifen raises clot risk, which is its most important adverse effect.

Stopping is not itself dramatic, but it lingers far longer than people assume: the medication guide says it can take about two months to clear, with the parent drug's half-life around 5-7 days and its major metabolite's around 14. The real question is what the axis does afterward: a recovery attempt either succeeded in restarting endogenous production or it did not, and that outcome is visible only on bloodwork weeks later, not from how stopping feels. Lingering effects are uncommon; the thrombosis risk falls once the drug is gone.

US: prescription-only (not scheduled). Grey-market "research liquid" is ubiquitous and variable.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
  Lancet Oncol, 2022
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
  Lancet, 2015
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
  Lancet, 2011

• Tamoxifen and pregnancyBreast · 2004
• [Tamoxifen, a high-potential molecule to treat all centronuclear myopathies]Med Sci (Paris) · 2024
• TamoxifenNurse Pract Forum · 1993
• Crosstalk of methylation and tamoxifen in breast cancer (Review)Mol Med Rep · 2024
• Individualization of tamoxifen therapy: much more than just CYP2D6 genotypingCancer Treat Rev · 2015
• Adducts and tamoxifenSemin Oncol · 1997
• Tamoxifen in men: a review of adverse eventsAndrology · 2016
• Tamoxifen and CYP2D6: a contradiction of dataOncologist · 2012
• Tamoxifen and the female reproductive tractExpert Opin Pharmacother · 2001
• [Tamoxifen flare]Zentralbl Gynakol · 1994
• Use of tamoxifen before and during pregnancyOncologist · 2011
• Tailored Tamoxifen Treatment for Breast Cancer Patients: A PerspectiveClin Breast Cancer · 2015